Participated · Series C · Nov 2024

TransMedics, founded in 1998, develops the Organ Care System, an investigational organ transport device designed to maintain organs in a warm, functioning state outside the body. The system aims to optimize organ health during transport, increase the number of usable donor organs, and enable living organ transplant. TransMedics recently initiated the European PROTECT trial to evaluate the Organ Care System for heart transplants. The company plans to extend the platform to other organs, including lung, liver and kidneys, and to commercialize the device. It is privately held and raised $29.75 million in Series C financing to accelerate growth, continue the PROTECT trial, and initiate new studies in Europe and the U.S. Company leadership indicated a target for European market approval early in 2007. TransMedics Group is a medical technology company built to address the need for more and better donor organs by developing portable extracorporeal warm perfusion and organ assessment technologies. The company’s Organ Care System (OCS) program focuses on preserving organ quality and assessing viability prior to transplant to potentially increase donor-organ utilization for end-stage heart, lung, and liver failure. TransMedics plans to use incremental growth capital to accelerate its commercial momentum, grow transplant volume, and improve clinical outcomes. The company said the new financing is non-dilutive and will provide financial flexibility as it scales the business. TransMedics was founded in 1998 and is headquartered in Andover, Massachusetts. The company intends to use the capital to retire existing debt and support continued market expansion. TransMedics has developed the Organ Care System (OCS), a portable technology and multi-organ platform designed to maintain donor organs in a near-physiologic state outside the body to improve transplant outcomes and expand the pool of transplantable organs. The company’s OCS Heart and OCS Lung systems are CE Marked and are used by transplant centers in Europe, Australia and Canada. The OCS Heart, Lung and Liver systems are in clinical trials in the United States. TransMedics is led by Dr. Waleed Hassanein, President and CEO. The company recently closed a $51.2M growth equity financing. TransMedics develops a portable warm blood perfusion system—referred to in coverage as an Organ Care System—that keeps donor organs functioning outside the body instead of on ice. The device is positioned as a “living organ transplant” solution intended to improve organ condition prior to transplant surgery. Reported benefits include the ability to resuscitate hearts from donors after circulatory death and to identify pathologically abnormal hearts that might be missed with cold static storage. A study and accompanying editorial in The Lancet found short-term outcomes comparable to cold storage but noted the system could reveal abnormalities and that more study is needed. The privately held Boston company was launched in 1998 and has raised well over $100 million to date, leaving it well-capitalized. CEO Waleed Hassanein has publicly criticized cooler-based transport and promoted the system as a better method for organ preservation and transport. TransMedics is an Andover, Massachusetts–based medical technology company focused on extending the life-saving benefits of organ transplantation. Led by President and CEO Dr. Waleed Hassanein, the company develops the Organ Care System (OCS™) Heart and Lung devices. The OCS devices are portable preservation technologies that maintain donor organs in a near-physiologic and functioning condition from donor to transplant recipient. TransMedics closed a $36M financing to support its programs. The company intends to use the funding to complete its heart and lung FDA pivotal trials and expand global commercial activities. In conjunction with the financing, representatives from the lead investor joined TransMedics’ Board of Directors.

Participated · Series B · Sep 2015

Farmigo runs a consumer marketplace where customers preorder farm-fresh groceries and pick them up at local “food communities” such as schools or offices. The company began by building software for farmers but shifted its focus to the consumer marketplace while continuing to develop an end-to-end ERP that tracks inventory, preorders, packing, and driver workflows. That technology is core to its model, which avoids home delivery by concentrating distribution at pickup sites. Farmigo positions its service as a convenient alternative to farmers’ markets and a more flexible option than traditional community-supported agriculture. It is available in New York City, New Jersey, and Northern California and plans to launch in Seattle–Tacoma on October 14. The company reports selling to more than 15,000 families and adding about 2,000 new families each month. Farmigo runs a "local food communities" program that brings a farmer's-market-style offering into workplaces, schools and community centers via dedicated online sites. The service gives each community access to a group of local farms and lets members order seasonal fruit, vegetables, eggs, meats, fish, bread, cheeses, wine and coffee for delivery. Orders are fulfilled and delivered to the community location within 48 hours of harvest. Farmigo pilots the program with companies in San Francisco and New York (including Etsy, Kiva and Carrot Creative) and recommends starting communities through specific organizations to simplify logistics and security. The company uses a Kickstarter-like commitment model to ensure farms have sufficient demand and says communities typically need roughly a 100-person office or 80–100 families to work; one pilot (Carrot Creative) saw about 75% adoption with company subsidies. Farmigo has also signaled product expansion (including future meal-planning features) and recently raised new financing to support growth.

Participated · Series B · Oct 2010

VetCentric, Inc. is a Baltimore, Washington-based company that supplies FDA- and EPA-approved pharmaceuticals, compounded medications, and therapeutic and wellness diets to pet owners through veterinary clinics. The company operates a home delivery solution that enables veterinarians to offer delivery convenience to their clients. VetCentric raised $3M in a Series B funding round to further develop that home delivery solution. The financing was structured as a Series B equity round. The investment was equally supported by Sherbrooke Capital, The Asset Management Company and the Nestle Venture Capital Fund (part of Nestle S.A.). The fundraising was reported by FinSMEs on 27/10/2010.

Participated · Equity · Apr 2010

Adina for Life is a San Francisco-based producer of natural and organic beverages, best known for its Adina Holistics product line. The company completed a $14M equity financing to support its growth. The round was led by Dallas, TX-based CIC Partners and included participation from Sherbrooke Capital, Pacific Community Ventures, Good Capital, Seraph Capital and many of Adina’s distributor partners. Adina said it will use the proceeds to bolster national distribution of its flagship Adina Holistics products. In conjunction with the financing, Roger Enrico (former Chairman and CEO of PepsiCo and Chairman of DreamWorks Animation SKG) and Michael Rawlings (managing partner at CIC Partners) will assume board positions. The company also named Norman E. Snyder as its new President and Chief Operating Officer last month.